FDA clears Cordis' Empira catheters

The FDA has cleared Cordis' EMPIRA and EMPIRA NC RX PTCA dilatation catheters for the treatment of coronary artery disease. The U.S. launch is expected early next year. "The EMPIRA Balloon Catheters offer our most advanced technology designed to treat challenging coronary artery disease," explained Campbell Rogers, Cordis chief scientific officer, global head R&D. "Cordis worked closely with our physician-customers and incorporated their feedback into the design of these next generation devices." Cordis release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.